BioNexus Gene Lab Corp. Cash and Restricted Cash
BioNexus Gene Lab Corp. (BGLC) had Cash and Restricted Cash of $2.39 million as of 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Cash
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-14
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $2.39M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $1.34M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $2.49M; Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents as first filed $2.38M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $1.15M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents as first filed |
|---|---|---|
| 2026-06-30 | $2.39M 10-Q · filed 2026-08-14 | |
| 2026-03-31 | $1.34M 10-Q · filed 2026-05-15 | |
| 2025-12-31 | $2.49M 10-Q · filed 2026-08-14 | $2.38M 10-K · filed 2026-04-14 |
| 2025-09-30 | $1.15M 10-Q · filed 2025-11-14 | |
| 2025-06-30 | $1.54M 10-Q · filed 2026-08-14 | $814.18K 10-Q · filed 2025-08-18 |
| 2025-03-31 | $2.09M 10-Q · filed 2025-05-15 | |
| 2024-12-31 | $2.89M 10-Q · filed 2026-08-14 | |
| 2024-09-30 | $4.14M 10-Q · filed 2024-11-15 | |
| 2024-06-30 | $5.41M 10-Q · filed 2024-08-14 | |
| 2024-03-31 | $4.44M 10-Q · filed 2025-05-15 | $5.83M 10-Q · filed 2024-05-15 |
| 2023-12-31 | $4.52M 10-Q · filed 2025-05-15 | $5.93M 10-K · filed 2024-04-16 |
| 2023-09-30 | $6.15M 10-Q · filed 2024-11-15 | |
| 2023-06-30 | $1.76M 10-Q · filed 2024-08-14 | |
| 2023-03-31 | $1.97M 10-Q · filed 2024-05-15 | |
| 2022-12-31 | $2.12M 10-K · filed 2025-04-15 | |
| 2022-09-30 | $1.46M 10-Q/A · filed 2024-03-26 | |
| 2022-06-30 | $1.34M 10-Q · filed 2023-08-16 | |
| 2022-03-31 | $1.84M 10-Q · filed 2023-05-09 | |
| 2021-12-31 | $2.12M 10-K · filed 2024-04-16 | |
| 2021-09-30 | $1.70M 10-Q · filed 2022-11-14 | |
| 2021-06-30 | $1.48M 10-Q · filed 2022-08-15 | |
| 2020-12-31 | $2.79M 10-K · filed 2023-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |